Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 9, Pages 2392
Publisher
MDPI AG
Online
2020-08-24
DOI
10.3390/cancers12092392
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer
- (2020) F. Mosele et al. ANNALS OF ONCOLOGY
- Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer
- (2020) S. Adams et al. ANNALS OF ONCOLOGY
- Pembrolizumab plus chemotherapy as neoadjuvant treatment for high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
- (2020) P. Schmid et al. ANNALS OF ONCOLOGY
- AJCC 8th edition prognostic staging provides no better discriminatory ability in prognosis than anatomical staging in triple negative breast cancer
- (2020) Jiehua He et al. BMC CANCER
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The contribution of germline predisposition gene mutations to clinical subtypes of invasive breast cancer from a clinical genetic testing cohort
- (2020) Chunling Hu et al. JNCI-Journal of the National Cancer Institute
- Predictors of Distant Metastases in Triple-Negative Breast Cancer Without Pathologic Complete Response After Neoadjuvant Chemotherapy
- (2020) William R. Kennedy et al. Journal of the National Comprehensive Cancer Network
- AKT inhibition improves OS in TNBC
- (2020) David Killock Nature Reviews Clinical Oncology
- Tissue-resident memory T cells in breast cancer control and immunotherapy responses
- (2020) Ann Byrne et al. Nature Reviews Clinical Oncology
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression and clinical significance of MAPK and EGFR in triple‑negative breast cancer
- (2020) Weihua Jiang et al. Oncology Letters
- Time Course and Management of Key Adverse Events During the Randomized Phase 3 SOLAR-1 Study of PI3K Inhibitor Alpelisib Plus Fulvestrant in Patients With HR-Positive Advanced Breast Cancer
- (2020) H.S. Rugo et al. ANNALS OF ONCOLOGY
- Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
- (2020) T. Karn et al. ANNALS OF ONCOLOGY
- Spectrum of PALB2 germline mutations and characteristics of PALB2‐related breast cancer: Screening of 16,501 unselected patients with breast cancer and 5890 controls by next‐generation sequencing
- (2020) Jiaojiao Zhou et al. CANCER
- NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response
- (2020) Sandra M Swain et al. CLINICAL CANCER RESEARCH
- TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer
- (2020) Hope S Rugo et al. Future Oncology
- The Landscape of Targeted Therapies in TNBC
- (2020) Elena Vagia et al. Cancers
- Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges
- (2020) Jin Sun Lee et al. Cancers
- Molecular Trajectory of BRCA1 and BRCA2 Mutations
- (2020) Yuichiro Hatano et al. Frontiers in Oncology
- Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36,480 cases
- (2020) Lin-Yu Xia et al. World Journal of Surgical Oncology
- Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer
- (2020) Milan Radovich et al. JAMA Oncology
- Insights into the Role of Estrogen Receptor β in Triple-Negative Breast Cancer
- (2020) Assunta Sellitto et al. Cancers
- A novel approach to triple-negative breast cancer molecular classification reveals a luminal immune-positive subgroup with good prognoses
- (2019) Guillermo Prado-Vázquez et al. Scientific Reports
- Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment
- (2019) Ana C. Garrido-Castro et al. Cancer Discovery
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- (2019) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer statistics for African Americans, 2019
- (2019) Carol E. DeSantis et al. CA-A CANCER JOURNAL FOR CLINICIANS
- OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
- (2019) M E Robson et al. ANNALS OF ONCOLOGY
- Targeting the PI3-kinase pathway in triple-negative breast cancer
- (2019) J Pascual et al. ANNALS OF ONCOLOGY
- Recent advances in triple negative breast cancer: the immunotherapy era
- (2019) Antonio Marra et al. BMC Medicine
- TP53 Status and Estrogen Receptor-Beta in Triple-Negative Breast Cancer: Company Matters
- (2019) Sunil S Badve et al. JNCI-Journal of the National Cancer Institute
- Chemotherapy as a TONIC to invigorate PD-1 inhibition in TNBC
- (2019) David Killock Nature Reviews Clinical Oncology
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state
- (2019) Gloria V. Echeverria et al. Science Translational Medicine
- Cancer treatment and survivorship statistics, 2019
- (2019) Kimberly D. Miller et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Poly(ADP-ribose) polymerase-1 antagonizes DNA resection at double-strand breaks
- (2019) Marie-Christine Caron et al. Nature Communications
- Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab
- (2019) Suzanne L. Topalian et al. JAMA Oncology
- PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review
- (2019) Planes-Laine et al. Cancers
- Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study
- (2019) Shristi Bhattarai et al. Cancers
- A Review of the Hereditary Component of Triple Negative Breast Cancer: High- and Moderate-Penetrance Breast Cancer Genes, Low-Penetrance Loci, and the Role of Nontraditional Genetic Elements
- (2019) Darrell L. Ellsworth et al. Journal of Oncology
- Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy
- (2019) Clémence Pinard et al. BREAST CANCER RESEARCH AND TREATMENT
- Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination
- (2019) Sandra M. Swain et al. BREAST CANCER RESEARCH AND TREATMENT
- Optimized immunohistochemical detection of estrogen receptor beta using two validated monoclonal antibodies confirms its expression in normal and malignant breast tissues
- (2019) John R. Hawse et al. BREAST CANCER RESEARCH AND TREATMENT
- Drug repurposing for breast cancer therapy: Old weapon for new battle
- (2019) Sadhna Aggarwal et al. SEMINARS IN CANCER BIOLOGY
- Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review
- (2019) Jessa Gilda P. Pandy et al. BMC CANCER
- Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial
- (2019) Mark Robson et al. EUROPEAN JOURNAL OF CANCER
- Impact of pathologic complete response on survival after neoadjuvant chemotherapy in early-stage breast cancer: a population-based analysis
- (2019) Nathalie LeVasseur et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Peter Schmid et al. LANCET ONCOLOGY
- Building momentum for subsets of patients with advanced triple-negative breast cancer
- (2019) Wendy A Woodward LANCET ONCOLOGY
- PARP inhibitor pick-me-up
- (2019) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells
- (2019) Sylvie M. Noordermeer et al. TRENDS IN CELL BIOLOGY
- Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis
- (2019) Yan Li et al. BREAST CANCER RESEARCH AND TREATMENT
- Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
- (2019) Peter Schmid et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
- (2019) Dennis J. Slamon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular stratification within triple-negative breast cancer subtypes
- (2019) Dong-Yu Wang et al. Scientific Reports
- Recruitment of CD103+ dendritic cells via tumor-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy
- (2019) John-Michael Williford et al. Science Advances
- Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review
- (2018) Ricardo L. B. Costa et al. BREAST CANCER RESEARCH AND TREATMENT
- Differences in Breast Cancer Survival by Molecular Subtypes in the United States
- (2018) Nadia Howlader et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study
- (2018) Peter A. Fasching et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
- (2018) Tiffany A. Traina et al. JOURNAL OF CLINICAL ONCOLOGY
- Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression
- (2018) Yuka Asano et al. Journal of Translational Medicine
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
- (2018) Carsten Denkert et al. LANCET ONCOLOGY
- Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
- (2018) Sibylle Loibl et al. LANCET ONCOLOGY
- Therapeutic landscape in mutational triple negative breast cancer
- (2018) Yaqin Shi et al. Molecular Cancer
- Immunotherapy: HLA-1 genotype influences response to checkpoint inhibitors
- (2018) Peter Sidaway Nature Reviews Clinical Oncology
- Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
- (2018) Alan Ashworth et al. Nature Reviews Clinical Oncology
- Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010–2014
- (2018) Mary C. Schroeder et al. ONCOLOGIST
- Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
- (2018) Angela Santonja et al. Oncotarget
- The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
- (2018) David M. Goldenberg et al. Oncotarget
- A New Strategy to Control and Eradicate “Undruggable” Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology
- (2018) Robert Van Sciver et al. Cancers
- Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria
- (2018) Juliane Hoyer et al. BMC CANCER
- Genetic Markers in Triple-Negative Breast Cancer
- (2018) Zuzana Sporikova et al. Clinical Breast Cancer
- The comings and goings of PARP-1 in response to DNA damage
- (2018) John M. Pascal DNA REPAIR
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- ERβ-mediated induction of cystatins results in suppression of TGFβ signaling and inhibition of triple-negative breast cancer metastasis
- (2018) Jordan M. Reese et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Estrogen receptor-beta is a potential target for triple negative breast cancer treatment
- (2018) David Austin et al. Oncotarget
- Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer
- (2018) Jieun Lee et al. Cancer Research and Treatment
- Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple negative breast cancer patients after neo-adjuvant chemotherapy
- (2018) S J Luen et al. ANNALS OF ONCOLOGY
- Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer
- (2018) Paul Gass et al. BMC CANCER
- Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation
- (2018) Giacomo Pelizzari et al. CANCER TREATMENT REVIEWS
- Benefit in patients with PD-L1-positive TNBC
- (2018) Diana Romero Nature Reviews Clinical Oncology
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anthracyclines in Early Breast Cancer: The ABC Trials—USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology)
- (2017) Joanne L. Blum et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype
- (2017) W. Fraser Symmans et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
- (2017) Aditya Bardia et al. JOURNAL OF CLINICAL ONCOLOGY
- NCCN Guidelines Insights: Breast Cancer, Version 1.2017
- (2017) William J. Gradishar et al. Journal of the National Comprehensive Cancer Network
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
- (2017) Jacob Schachter et al. LANCET
- Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2017) Sung-Bae Kim et al. LANCET ONCOLOGY
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
- (2017) Norikazu Masuda et al. NEW ENGLAND JOURNAL OF MEDICINE
- PARP inhibitors: Synthetic lethality in the clinic
- (2017) Christopher J. Lord et al. SCIENCE
- Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer
- (2017) Maria Vittoria Dieci et al. SEMINARS IN CANCER BIOLOGY
- The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC)
- (2017) Nobumoto Tomioka et al. Breast Cancer
- The survival benefit of neoadjuvant chemotherapy and pCR among patients with advanced stage triple negative breast cancer
- (2017) Tithi Biswas et al. Oncotarget
- ERβ inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer
- (2017) Jordan M. Reese et al. Oncotarget
- Expression of PD-L1 and prognosis in breast cancer: a meta-analysis
- (2017) Minghui Zhang et al. Oncotarget
- Health Disparities and Triple-Negative Breast Cancer in African American Women
- (2017) Lisa A. Newman et al. JAMA Surgery
- Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC
- (2017) Natasha K. Brockwell et al. Cancer Immunology Research
- Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas
- (2017) Dezheng Huo et al. JAMA Oncology
- Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer
- (2017) Reva K. Basho et al. JAMA Oncology
- Breast Cancer Screening and Diagnosis
- (2017) Therese B. Bevers et al. Journal of the National Comprehensive Cancer Network
- Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer
- (2016) R. Bell et al. ANNALS OF ONCOLOGY
- A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)
- (2016) H. Bonnefoi et al. ANNALS OF ONCOLOGY
- The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40
- (2016) Harry D. Bear et al. ANNALS OF SURGICAL ONCOLOGY
- Agonists and knockdown of estrogen receptor β differentially affect invasion of triple-negative breast cancer cells in vitro
- (2016) Susanne Schüler-Toprak et al. BMC CANCER
- SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer
- (2016) Z. A. Nahleh et al. BREAST CANCER RESEARCH AND TREATMENT
- Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities
- (2016) Carol E. DeSantis et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Targeting Estrogen Receptor Beta in a Phase 2 Study of High-Dose Estradiol in Metastatic Triple-Negative Breast Cancer: A Wisconsin Oncology Network Study
- (2016) Kari B. Wisinski et al. Clinical Breast Cancer
- Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome
- (2016) Rhiannon K Beckers et al. HISTOPATHOLOGY
- PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas
- (2016) Ashley Cimino-Mathews et al. HUMAN PATHOLOGY
- Biomarkers of residual disease after neoadjuvant therapy for breast cancer
- (2016) Frederique Penault-Llorca et al. Nature Reviews Clinical Oncology
- Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
- (2016) Giampaolo Bianchini et al. Nature Reviews Clinical Oncology
- I-SPY 2 — Toward More Rapid Progress in Breast Cancer Treatment
- (2016) Lisa A. Carey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biology and Management of Patients With Triple-Negative Breast Cancer
- (2016) P. Sharma ONCOLOGIST
- Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer
- (2016) Domenico Ribatti et al. Translational Oncology
- First Anti-PD-L1 Drug Approved for NSCLC
- (2016) Cancer Discovery
- SIAH and EGFR, Two RAS Pathway Biomarkers, are Highly Prognostic in Locally Advanced and Metastatic Breast Cancer
- (2016) Lauren L. Siewertsz van Reesema et al. EBioMedicine
- Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
- (2016) Brian D. Lehmann et al. PLoS One
- Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
- (2015) M. V. Dieci et al. ANNALS OF ONCOLOGY
- Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration
- (2015) V. Bossuyt et al. ANNALS OF ONCOLOGY
- Landscape of Neoadjuvant Therapy for Breast Cancer
- (2015) Tufia C. Haddad et al. ANNALS OF SURGICAL ONCOLOGY
- Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy
- (2015) Aleix Prat et al. BMC Medicine
- Therapeutic targets of triple-negative breast cancer: a review
- (2015) Vinayak S Jamdade et al. BRITISH JOURNAL OF PHARMACOLOGY
- Breast cancer statistics, 2015: Convergence of incidence rates between black and white women
- (2015) Carol E. DeSantis et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States
- (2015) Sarah S. Mougalian et al. CANCER
- Tumor Heterogeneity: Focus on the Leaves, the Trees, or the Forest?
- (2015) Joel S. Parker et al. CANCER CELL
- ER Expression and Breast Cancer Risk Prediction for Women with Atypias
- (2015) T. J. Hieken et al. Cancer Prevention Research
- Ras Signaling Is a Key Determinant for Metastatic Dissemination and Poor Survival of Luminal Breast Cancer Patients
- (2015) K. L. Wright et al. CANCER RESEARCH
- Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer
- (2015) Giovanni Ciriello et al. CELL
- Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
- (2015) Padmanee Sharma et al. CELL
- Receptor Status Change From Primary to Residual Breast Cancer After Neoadjuvant Chemotherapy and Analysis of Survival Outcomes
- (2015) Napa Parinyanitikul et al. Clinical Breast Cancer
- The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer
- (2015) A. DeMichele et al. CLINICAL CANCER RESEARCH
- Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019
- (2015) C. Paoletti et al. CLINICAL CANCER RESEARCH
- RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
- (2015) S. Loi et al. CLINICAL CANCER RESEARCH
- Therapies for triple negative breast cancer
- (2015) Eleni Andreopoulou et al. EXPERT OPINION ON PHARMACOTHERAPY
- Differences in Breast Cancer Stage at Diagnosis and Cancer-Specific Survival by Race and Ethnicity in the United States
- (2015) Javaid Iqbal et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers
- (2015) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
- (2015) William M. Sikov et al. JOURNAL OF CLINICAL ONCOLOGY
- TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
- (2015) Steven J. Isakoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial
- (2015) Harry D Bear et al. LANCET ONCOLOGY
- Toward understanding and exploiting tumor heterogeneity
- (2015) Ash A Alizadeh et al. NATURE MEDICINE
- Clinical management of breast cancer heterogeneity
- (2015) Dimitrios Zardavas et al. Nature Reviews Clinical Oncology
- Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy
- (2015) Tari A. King et al. Nature Reviews Clinical Oncology
- Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
- (2015) Sara M. Tolaney et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients
- (2015) Giuseppina Rosaria Rita Ricciardi et al. PLoS One
- Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy
- (2014) A. Sheri et al. ANNALS OF ONCOLOGY
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- (2014) R. Salgado et al. ANNALS OF ONCOLOGY
- Neoadjuvant Strategies for Triple Negative Breast Cancer: ‘State-of-the-art’ and Future Perspectives
- (2014) Luisa Carbognin et al. Anti-Cancer Agents in Medicinal Chemistry
- ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer
- (2014) Jordan M Reese et al. BMC CANCER
- Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
- (2014) M. D. Burstein et al. CLINICAL CANCER RESEARCH
- Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients
- (2014) Jordan Madic et al. INTERNATIONAL JOURNAL OF CANCER
- Outcomes by Tumor Subtype and Treatment Pattern in Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study
- (2014) Ines Vaz-Luis et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparative Effectiveness of Neoadjuvant Therapy for HER2–Positive Breast Cancer: A Network Meta-Analysis
- (2014) Aiko Nagayama et al. JNCI-Journal of the National Cancer Institute
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- (2014) Patricia Cortazar et al. LANCET
- Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
- (2014) Gunter von Minckwitz et al. LANCET ONCOLOGY
- Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry
- (2014) Abenaa M Brewster et al. LANCET ONCOLOGY
- Combining chemo-, hormonal and targeted therapies to treat breast cancer (Review)
- (2014) James McCubrey et al. Molecular Medicine Reports
- TNBC: can we treat the untargetable?
- (2014) Lisa Hutchinson Nature Reviews Clinical Oncology
- Drugging the undruggable RAS: Mission Possible?
- (2014) Adrienne D. Cox et al. NATURE REVIEWS DRUG DISCOVERY
- Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy
- (2014) Kunpeng Wu et al. World Journal of Surgical Oncology
- Current Approaches and Challenges in Monitoring Treatment Responses in Breast Cancer
- (2014) Lindsey J. Graham et al. Journal of Cancer
- PD-L1 Expression in Triple-Negative Breast Cancer
- (2014) E. A. Mittendorf et al. Cancer Immunology Research
- First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients
- (2013) D. W. Miles et al. ANNALS OF ONCOLOGY
- Outcomes of Delays in Time to Treatment in Triple Negative Breast Cancer
- (2013) Amy Eastman et al. ANNALS OF SURGICAL ONCOLOGY
- Breast cancer statistics, 2013
- (2013) Carol DeSantis et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer
- (2013) Kamal S. Saini et al. CANCER TREATMENT REVIEWS
- Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes
- (2013) H. Masuda et al. CLINICAL CANCER RESEARCH
- Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models
- (2013) J. Lin et al. CLINICAL CANCER RESEARCH
- Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer
- (2013) A. Gucalp et al. CLINICAL CANCER RESEARCH
- Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer
- (2013) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
- (2013) David Cameron et al. LANCET ONCOLOGY
- Research Resource: Global Identification of Estrogen Receptor β Target Genes in Triple Negative Breast Cancer Cells
- (2013) Erin K. Shanle et al. MOLECULAR ENDOCRINOLOGY
- BEATRICE bevacizumab trial—every cloud has a silver lining
- (2013) Lisa Hutchinson Nature Reviews Clinical Oncology
- Emerging targeted agents in metastatic breast cancer
- (2013) Dimitrios Zardavas et al. Nature Reviews Clinical Oncology
- Cancer Genome Landscapes
- (2013) B. Vogelstein et al. SCIENCE
- Neoadjuvant Chemotherapy in the Treatment of Breast Cancer
- (2013) Meredith H. Redden et al. SURGICAL CLINICS OF NORTH AMERICA
- Triple-negative breast cancer: epidemiological considerations and recommendations
- (2012) P. Boyle ANNALS OF ONCOLOGY
- Neoadjuvant treatment of breast cancer
- (2012) A. M. Thompson et al. ANNALS OF ONCOLOGY
- Cellular Heterogeneity and Molecular Evolution in Cancer
- (2012) Vanessa Almendro et al. Annual Review of Pathology-Mechanisms of Disease
- Role of epidermal growth factor receptor in breast cancer
- (2012) Hiroko Masuda et al. BREAST CANCER RESEARCH AND TREATMENT
- Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy
- (2012) Amye J. Tevaarwerk et al. CANCER
- Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network
- (2012) Nancy U. Lin et al. CANCER
- Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer
- (2012) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Defining the Benefits of Neoadjuvant Chemotherapy for Breast Cancer
- (2012) Anne F. Schott et al. JOURNAL OF CLINICAL ONCOLOGY
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
- (2012) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
- (2012) Lisa A. Carey et al. JOURNAL OF CLINICAL ONCOLOGY
- Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657
- (2012) Laura J. Esserman et al. JOURNAL OF CLINICAL ONCOLOGY
- Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
- (2012) B. R. Davies et al. MOLECULAR CANCER THERAPEUTICS
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
- (2012) Harry D. Bear et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
- (2012) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intratumor Heterogeneity: Seeing the Wood for the Trees
- (2012) T. A. Yap et al. Science Translational Medicine
- Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer
- (2012) Hiroki Nakajima et al. Breast Cancer
- Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
- (2011) Laura J. Esserman et al. BREAST CANCER RESEARCH AND TREATMENT
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Age and Survival Estimates in Patients Who Have Node-Negative T1ab Breast Cancer by Breast Cancer Subtype
- (2011) Rachel L. Theriault et al. Clinical Breast Cancer
- Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer
- (2011) A. M. Gonzalez-Angulo et al. CLINICAL CANCER RESEARCH
- Heterogeneity in breast cancer
- (2011) Kornelia Polyak JOURNAL OF CLINICAL INVESTIGATION
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival
- (2011) Sylvain Ladoire et al. JOURNAL OF PATHOLOGY
- PARP inhibitors stumble in breast cancer
- (2011) Malini Guha NATURE BIOTECHNOLOGY
- Treatment of HER2-positive breast cancer: current status and future perspectives
- (2011) Carlos L. Arteaga et al. Nature Reviews Clinical Oncology
- A review of PARP inhibitors: from bench to bedside
- (2010) C. Underhill et al. ANNALS OF ONCOLOGY
- Triple negative breast cancer: unmet medical needs
- (2010) Sumanta Kumar Pal et al. BREAST CANCER RESEARCH AND TREATMENT
- Increased SIAH expression predicts ductal carcinoma in situ (DCIS) progression to invasive carcinoma
- (2010) Kathryn C. Behling et al. BREAST CANCER RESEARCH AND TREATMENT
- Triple-Negative Breast Cancer
- (2010) Steven J. Isakoff CANCER JOURNAL
- Triple-negative breast cancer: disease entity or title of convenience?
- (2010) Lisa Carey et al. Nature Reviews Clinical Oncology
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
- (2009) B. Corkery et al. ANNALS OF ONCOLOGY
- Triple-negative breast cancer--current status and future directions
- (2009) O. Gluz et al. ANNALS OF ONCOLOGY
- Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer
- (2009) Miguel Martín et al. BREAST CANCER RESEARCH AND TREATMENT
- Ras/Raf-1/MAPK Pathway Mediates Response to Tamoxifen but not Chemotherapy in Breast Cancer Patients
- (2009) L. M. McGlynn et al. CLINICAL CANCER RESEARCH
- Pattern of metastatic spread in triple-negative breast cancer
- (2008) Rebecca Dent et al. BREAST CANCER RESEARCH AND TREATMENT
- Basal-Like Breast Cancer: A Critical Review
- (2008) Emad A. Rakha et al. JOURNAL OF CLINICAL ONCOLOGY
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
- (2008) Cornelia Liedtke et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of Disrupting Seven-in-Absentia Homolog 2 Function on Lung Cancer Cell Growth
- (2008) Atique U. Ahmed et al. JNCI-Journal of the National Cancer Institute
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started